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Introduction: In the surgical management of the patients with Cushing syndrome (CS), minimal invasive
adrenalectomy (MA) has become the procedure of choice to treat adrenal tumors with a benign
appearance 6 cm in diameter. Authors evaluated medium- and long-term outcomes of laparoscopic
adrenalectomy (LA) for CS or subclinical CS (sCS), performed for ten years in an endocrine surgery unit.
Methods: We retrospectively reviewed 21 consecutive patients undergone LA for CS or sCS from 2003 to
2013. Postoperative clinical and cardiovascular status modiﬁcations and surgical medium and long-term
outcomes were analyzed.
Results: In each patient surgery determined a normalization of the hormonal proﬁle. There was no
mortality neither major post-operative complications. Mean operative time was higher during the
learning curve, there was no conversion, and morbidity rate was 6.3%. Regression of the main clinical
symptoms occurred slowly in twelve months.
Conclusions: LA is a safe, effective and well-tolerated procedure for the treatment of CS and sCS reducing
arterial blood pressure, body weight and fasting glucose levels. Following the learning curve a morbidity
rate similar to that reported in the MA series for other adrenal diseases is observed.
© 2014 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction pathophysiology of the adrenal diseases, and an appropriate pre-Hypercortisolism in Cushing's syndrome (CS) caused by an
adrenocorticotrophic hormone (ACTH) producing pituitary tumor
(Cushing's disease), cortisol secretion (adrenal adenoma/carci-
noma), or ACTH hypersecretion by a not pituitary tumor remains a
severe and life-threatening disease. An estimated incidence ranging
from2 to3 permillionpopulationper year is reported [1].Minimally
invasive adrenalectomy (MA), thanks to a lower morbidity rate, a
shorter hospitalization, and a more rapid recovery than “open”
surgery, by increasingpatients' satisfactionandcomfort, hasbecome
the standard of care for the management of functioning and non-
functioning adrenal neoplasms with a benign appearance  6 cm
in diameter and weighing < 100 g [2]. Progresses in the ﬁelds of
anesthesiology and surgery, a better understanding of thezo).
f of Surgical Associates Ltd.operative blood pressure control, contributed to obtain better out-
comes also in the surgical management of CS [3,4]. Moreover, the
analysis of the available evidence data demonstrated that MA re-
mains the preferred treatment for subclinical CS (sCS) [4].
We report the results, from the last ten years, of a retrospective
analysis of 21 CS and sCS patients with adrenal lesions who had
undergone laparoscopic adrenalectomy (LA) in a referral university
unit of endocrine surgery. Medium and long-term outcomes were
compared with those reported during the same years following LA
for other adrenal diseases.
2. Materials and methods
2.1. Study design
Review of all recorded clinical data was performed for pa-
tients who underwent LA for adrenal neoplasms, between
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dentally discovered, and not associated with a predominant
hormonal secretion, was considered as an “incidentaloma”. Ac-
cording to Persy [5] in about 5e20% of these cases a sCS, con-
sisting in a subclinical cortisol hypersecretion, associated with
subtle alterations of the hypothalamicepitutitaryeadrenal
(HePeA) axis due to the adrenal autonomy, might be present. CS
diagnosis was based on blunted diurnal cortisol circadian rhythm
(plasma cortisol at 24.00/8.00 percent ratio > 50%), suppressed
ACTH concentrations (morning plasma ACTH < 10 pg/ml) and
elevated 24 h urinary free cortisol excretion (24 h urinary free
cortisol > 100 mg), combined with an abnormal result of at least
one other test of the HePeA axis such as 1 mg dexamethasone,
given between 23.00 and 24.00 h, and cortisol measured be-
tween 08.00 and 09.00 h the following morning or dexametha-
sone 2 mg/day orally, 0.5 mg every 6 h for 48 h, plasma cortisol
level  1.8 mg/dl with a cut-off value for suppression of 50 nmol/L
(1.8 g/dl) [6]. Impaired fasting glucose levels and diabetes were
deﬁned according to Alberti et al. [7]. A BMI >25 was classed as
obesity, a triglyceride serum levels >150 mg/dl, cholesterol
serum levels>220 mg/dl or statine therapy identiﬁed hyperlip-
idemia [8]. All subjects underwent clinical examination pre-
operatively and post-operatively at 6 and 12 months, recording
the presence of arterial hypertension, obesity, dislipidemia and
diabetes mellitus type 2. Apart from sCS or CS, surgical in-
dications for LA included pheochromocytomas (PCCs) up to 8 cm
in diameter, neoplasms (incidentalomas or adenomas associated
with a speciﬁc hormonal secretion and clinical syndrome) up to
6 cm, myelolipoma up to 12 cm, adrenal metastases < 6 cm, in
patients with an ASA risk not over level III, and age less than 80
years. Suspected primary malignant adrenal tumor was consid-
ered as a contraindication to LA. Outcomes measures for our
analysis were 30-day mortality and complications rate, and
functional medium and long-term results. An experienced
endocrine and laparoscopic surgeon, associated with a collabo-
rative team, performed all surgical procedures. In most cases,
patients were referred to surgery by regional endocrinology
units, following a comprehensive endocrinological assessment.
Demographic, surgical, pathological features and data about
intraoperative and postoperative blood pressure (BP) levels were
retrospectively collected. Diagnostic imaging consisted of ultra-
sonography, computed tomography (CT), magnetic resonance
imaging, metaiodobenzylguanidine scintigraphy in all PCC pa-
tients, in whom a genetic study looking for mutations of the RET
proto-oncogene was performed as well. Anesthesia charts and
pathology reports of each patient were obtained. In presence of a
diastolic blood pressure above 90 mmHg and systolic blood
pressure (SBP) levels > 150 mmHg hypertension was diagnosed;
SBP > 180 mmHg levels were considered hypertensive crises, and
levels < 90 mmHg were considered hypotensive crises. Alfa or
Beta blockers, calcium antagonists and angiotensin receptor
blockers represented the associated previous drug therapy.
Postoperatively, patients were not routinely admitted to the
Intensive Care Unit. In no patient peridural analgesia was
employed. Finally, in SC patients, hydrocortisone was given
quickly intraoperatively through an intravenous line (100 mg)
and the dose was postoperatively increased if signs of hypo-
cortisolism developed (fatigue, lethargy and fever). Patients were
discharged if they had no cardiovascular complains or pain, and
had begun oral feeding. Follow-up consisted of 6 month, then
yearly testing of blunted diurnal cortisol circadian rhythm
(plasma cortisol at 24.00/8.00 percent ratio > 50%), ACTH con-
centrations and 24 h urinary free cortisol excretion and abdom-
inopelvic CT scans with contrast agent. Data were analyzed using
descriptive statistics.2.2. Anaesthesia
Patients received general anesthesia. All operations were per-
formed using orotracheal intubation, without local anesthesia of
the upper airways. Invasive arterial pressure monitoring was
routinely used for PCC patients. A central venous catheter was
selectively previously placed. No pulmonary catheters were used.
Hemodynamic data were recorded. Heart rate, systolic and dia-
stolic blood pressure were recorded before the induction of
anesthesia, after CO2 inﬂation, before and after adrenalectomy.
After induction of anesthesia, by remifentanil (0.25 mcg/kg/min)
and propofol (2 mg/kg), cisatracurium besylate (0.2 mg/kg), which
was also used as muscle relaxant during surgery, was adminis-
tered. Anesthesia was maintained by the inhalation of sevoﬂurane
and nitrous oxide 50% in oxygen, supplemented with remifentanil
infusion. Muscle relaxation during the operation was maintained
with intermittent boluses. Blood loss and infused ﬂuid volume
during surgery were also recorded. Intraoperative treatment of
hypertensive crises was carried out according to previous re-
ported data [9e11].
2.3. Surgery
Operative time was considered as the period from skin incision
to wound dressing. An antibiotic and antithrombotic prophylactic
therapy was administered in all cases. Adrenalectomies were per-
formed using a standard transperitoneal lateral laparoscopic
approach, with 4 trocars if the tumorwas in the right adrenal gland,
and usually 3 trocars if it was in the left one [3]. The patients were
placed in the left or right lateral decubitus position (on the side
opposite to the tumor), of about 30 for right LA and of about 90
for left LA. In each case, pneumoperitoneumwas induced byHasson
trocar, according to the “open” technique, and was maintained at
12e14 mmHg with carbon dioxide (CO2). Harmonic scalpel™
(Ethicon Endo Surgery INC e Johnson & Johnson, NJ, USA) or
LigaSure™ vessel sealing system (Tyco, Boulder CO, USA) were
routinely employed for adrenal glands dissection. Whenever
necessary, a bipolar coagulation was routinely preferred for he-
mostasis. In the surgical intervention, the ﬁrst step in most cases
was the vascular control of the main adrenal vein by clips. In two
PCC cases, a linear stapler was utilized. If required, the lateral and
posterior connections of the right hepatic lobe were incised, so
retracting liver superiorly and medially, taking particular care in CS
patients, in whom liver may be very fragile. During a left LA, a wide
left colon mobilization is routinely carried out. The surgical speci-
mens were extracted in retrieval bags through a mini-laparotomy
at the site of one of the trocars. An off-suction 20 Fr drain was
routinely placed and removed after about 1e2 days. Full mobili-




Sixteen of 88 (18.2%) observed patients, 12 women and 4 men
(M:F ¼ 1:3), with a mean age of 43.6 years (range 22e74), were
considered affected by CS, and 5/88 (5.6%) by sCS, 3 women and 2
men, with a mean age of 52.6 years (range 36e68), were enrolled
for the analysis (Table 1). Functioning tumors were present in 49/88
cases (55.6%). Seventeen patients (19.3%) were affected by PCC, 16
(18.2%) by Conn's disease, 1 (1.1%) by a voluminous myelolipoma,
while in 34 cases (38.6%) an incidentaloma was present. In 2 cases
(2.7%) adrenal cysts were reported by deﬁnitive pathology. Two
metastases (one in the right and one in the left adrenal gland)
Table 1
Demographics and operative time.
CS sCS
Age (years) 43.6 (22e74) 52.6 (36e68)
Male/Female ratio 1/3 1/3
Mean size (cm) 2.1 (2e2.5) 1.7 (1.6e2)
Right site 11 2
Left site 8 1
Mean weight (gr) 19.6 (13.5e31.4) 17 (14e20)
Mean operative time (min) 144.3 (120e180) 143 (130e160)
Mean hospitalization (days) 4.1 (3e9) 4.3 (3e5)
CS: Cushing Syndrome; sCS: subclinical Cushing Syndrome.
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a breast and of a renal cancer, with a tumor mean size of 5.86 cm
(range 1.1e12). Aldosteronomas were associated with the smallest
size (1.1 cm), while myelolipoma was the largest observed
neoplasm (12 cm). A right adrenal gland tumor in 9/16 CS cases
(56.2%) and 1 bilateral tumor were reported, similar to that re-
ported in the entire series. Associated diseases in CS patients
included hypertension in 10/16 patients (62.5%), obesity in 9/16
patients (56.2%) insulin-dependent diabetes in 4/16 patients (25%)
and dilated cardiomyopathy in 3/16 patients (18.7%). Associated
pathologies in sCS patients included hypertension in 3/5 patients
(60%), insulin-dependent diabetes in 1/5 patients (20%). Patholog-
ical examination showed an adrenocortical adenoma in 9/16 CS
patients (56.2%) and in 3/5 sCS patients (60%), while a glandular
hyperplasia was identiﬁed in 7/16 (43.7%) CS cases and in 2/5 sCS
patients (40%). In each patient surgery determined a normalization
of the pathological hormonal serum levels. Mean follow-up was
56.8 month (6e120). Contralateral gland hyperplasia caused re-
lapsing disease in one female patient undergone left adrenalectomy
about twelve months before. Long-term results are summarized in
Table 2.
3.2. Surgery
Three of 16 (18.7%) patients underwent previous abdominal
surgery, with a laparoscopic or laparotomic approach. No simulta-
neous laparoscopic procedures were performed. Overall mean
operative time was 143.8 min (range 125e180) during the learning
curve and 121.3 min (range 100e160) in the further procedures.
Mean blood loss was 145.7 ml (range 50e220). In one female pa-
tient, muscle relaxation was not sufﬁcient to obtain a wide
“working space” by pneumoperitoneum. More technical difﬁculties
and operative timewere observed during the surgical operation. No
patient required intra or postoperative blood transfusion. Harmonic
scalpel™ (Ethicon Endo Surgery INCe Johnson & Johnson, NJ, USA)
or LigaSure™ vessel sealing system (Tyco, Boulder, CO, USA)
showed a similar efﬁcacy in tissue dissection and hemostasis con-
trol. There was no mortality. Two of 21 (9.5%) injuries of the splenic
and hepatic capsule, conservatively and successfully treated byTable 2
Laparoscopic adrenalectomy: long-term results (%).
Pre surgical data (CS þ sCS) Follow up data (CS þ sCS)
Persistence Regression
Hypertension 61.9 (13/21) 23.1 61.5
Obesity 31.7 (9/21) 33.4 66.6
IDDM 23.8 (5/21) 60 40
Dilated
cardiomyopathy
14.2 (3/21) 66.6 33.4
IDDM: insulin-dependent diabetes mellitus.Floseal ® Hemostatic Matrix (Baxter Zurich- Switzerland) and
oxidized cellulose (Tabotamp Fibrillar Johnson & Johnson, NJ, US),
were the most signiﬁcant observed intraoperative complications.
Conversion to open surgery was not reported. Mean hospitalization
was 4.2 days (range 3e9) (Table 1).
3.3. Morbidity
No postoperative mayor complication occurred. Thirty-day
morbidity rate was 18.7% (3/16 patients), and consisted of one
case of abdominal wall hematoma, one case of port site hernia, and
one intra-abdominal collection spontaneously resolved. Morbidity
rate was similar to that reported in the entire series. Pulmonary
embolism, acute renal failure, bleeding requiring transfusion, deep
venous thrombosis and sepsis were not observed during the 30
postoperative days.
3.4. Follow-up
LA was efﬁcacious in determining a normalization of the
endocrine proﬁle after 56.8 month long-term follow-up. Hyper-
tension was persistent in 3/13 cases (23.1%), disappeared in 8/13
patients (61.5%), while in 2/13 (15.4%) a reduction of number and
dose of antihypertensive drugs were observed. Obesity disappeared
in 6/9 patients (66.6%) and diabetes disappeared in 2/5 cases (40%),
while glucose intolerance was not reported. Cardiomyopathy per-
sisted in 2/3 cases (66.6%) (Table 2).
4. Discussion
During the last decades, advances and diffusion of diagnostic
imaging have determined a higher rate of incidentally discovered
adrenal masses, deﬁned as incidentalomas [3,12]. Most of these are
unsecretive, benign lesions, while in approximately 5e20% of the
cases a subclinical cortisol hypersecretion might be present, asso-
ciated with subtle alterations of the hypothal-
amicepituitaryeadrenal axis due to adrenal autonomy, a disorder
that has also been described as sCS [5]. Accordingly, corticotrophin
ACTH producing pituitary tumor e Cushing's Disease e adrenal
adenoma/carcinoma or ACTH hypersecretion by a non-pituitary
tumor may cause severe and life-threatening hypercortisolism in
CS. In 10e20% of patients an ectopic ACTH secretion and rarely,
ectopic corticotropin-releasing hormone (CRH) secretion can be
identiﬁed. The syndrome may be caused by a wide spectrum of
tumors, ranging from undetectable tumors to widespread meta-
static disease. However, in the majority of patients with ectopic CS,
a disseminated malignant disease is diagnosed [13]. In untreated
patients, signiﬁcant morbidity and potential mortality related to
life-threatening infections, diabetes mellitus, hypertension, and
increased risk associated with surgery have been reported [14].
Surgery, determining a reduction of arterial blood pressure, body
weight and fasting glucose was considered the treatment of choice
for clinical and subclinical SC [15e17]. Because of the high inci-
dence of co-morbidities in CS patients, surgical and perioperative
management has become challenging for surgeons. Fortunately,
thanks to a better management, physiopathologic knowledge and
technological progress during the last decades mortality decreased
totally [16]. Lower morbidity (3e20%) and mortality rates,
decreased postoperative pain, analgesic administration, ileus and
costs, shorter hospitalization, earlier return to work and a better
cosmetic result than those reported following open surgery, are the
main advantages of the retroperitoneoscopic or laparoscopic
adrenalectomy, largely established as the gold standard for small
benign adrenal lesions [2]. Previous laparotomic surgery may be
not considered as contraindication. Recovery from clinical
G. Conzo et al. / International Journal of Surgery 12 (2014) S107eS111S110syndromes associated with excessive hormonal secretion is the
major objective of surgery, but the large acceptance of the mini-
invasive approach extended the indications to the treatment of
incidentalomas >3.5e4 cm, cysts, glandular hyperplasia and me-
tastases [2,18e20].
In our experience, thanks to the improvement of surgical skills
and the technologic assistance (i.e. new dissection tools or intra-
operative ultrasound, very useful during a sparing adrenalectomy),
LA could be considered as the gold standard for the treatment of
benign adrenal diseases, in such cases with a diameter up to 12 cm
(myelolipoma) [4,21,22] with a very low morbidity rate similar to
that reported in other endocrinological diseases [23e25]. This
surgical approach was effective, safe and well tolerated in most
cases, with a very low morbidity rate, also following sCS, CS or PCC
treatment, considered at high risk for hemodynamic disorders
[9,21,22].
Authors analyzed their results throughout the discussion and
performed a literature review inhering mini invasive adrenalec-
tomy for SC. Although our study conﬁrms the previous published
data, it has several limitations. A single team composed by expe-
rienced endocrine and laparoscopic surgeons, in a tertiary referral
centre, operated patients mostly selected by referral endocrine
units. No patient underwent a retroperitoneal approach. Finally,
data were retrospectively evaluated and no comparison with an
“open” series was carried out.4.1. Demographics
The presented series includes patients mostly affected by a
clinical syndrome presenting complex clinical pictures and needing
often a preoperative medical treatment. CDs were associated with
cardiovascular disease, but nevertheless their morbidity rate was
similar to that observed in patients with sCDs or incidentalomas,
that were less frequently observed in our series. Regarding the
regression of clinical symptoms, it was observed in more than 50%
of the reported cases, with great satisfaction for patients.4.2. Surgical details
We considered the ﬁrst 30 operations as part of the learning
curve, but about 40 cases are needed before mastering the surgical
procedure. A higher risk of conversion to open surgery is identiﬁ-
able in patients affected by adrenal lesions greater than 8 cm and
needing concomitant surgical procedures that should be not
managed during the ﬁrst phase of experience without a tutor [4].
Our low rate of conversion, similar during the learning curve and
after this time for the entire series reﬂects the high proﬁciency in
advanced laparoscopic surgery of the operative team, as well as
conﬁrming the appropriate indications to LA.
A lateral position of about 30 is actually preferred in per-
forming a right LA, as well as, during a left LA, a wide left colon,
spleen and pancreatic tail mobilization is routinely carried out.
Finally, an ultrasonic dissector of recent conception (Harmonic
Ace® Ethicon Endo-Surgery INC e Johnson & Johnson, NJ, USA) is
considered as the preferred adrenal gland dissection instrument,
and resulted very useful in maintaining a near bloodless ﬁeld, as
well as reported in the management of other endocrine diseases
[23,24]. Robotic approach showed several advantages -the 3-
dimensional view, wristed instrument, and stable camera plat-
form- more useful for removing large adrenal tumors [25e27].
Training and cost are the two major concerns for robotic adrenal-
ectomy, and more prospective studies are needed to exactly deﬁne
the role of robotics in adrenal surgery [28].4.3. Morbidity and outcomes
Large indeterminate adrenal neoplasm, carcinoma, tumor size
>6 cm, and the need for concomitant surgical procedures are
considered themajor variables predicting the 30-day morbidity [4].
By analyzing the available literature data, mortality was reported
during the postoperative period in high-risk patients, and a careful
multidisciplinary and long-term management is recommended
[16]. According to our experience, in Cushing's diseases, a higher
post-operative infectious complication rate was not observed. In no
patient pancreatitis or torsion of splenic vessels were observed.
Considering CS as a bilateral adrenal disease, the role of ultrasound
assisted sparing adrenalectomy should be carefully considered,
especially in young patients. However, its indication remains
controversial. In case of intraoperative complications, a conversion
to open surgery was not necessary, and a “conservative” manage-
ment of the splenic and hepatic capsule injuries was easily per-
formed, without excessive risks for the patients.
4.4. Learning points
Regression of CS or sCS symptoms is mostly slow, but clinical
advantages following surgery are undeniable and so an operative
treatment is mandatory. LA is safe and feasible also for large adrenal
lesions and an additional port may be very useful, especially in case
of complications. According to the available evidence data CS sur-
gery may be associated with higher operative time, complications
and conversion rate, and an experienced operative team is needed.
Previous laparotomic surgery might be not considered as a
contraindication to the laparoscopic approach, moreover, the sur-
gical skill required is proportional to the tumor size. A collaborative
management, between endocrine physician, surgeon and anaes-
thesiologist is recommended in referral high volume units, espe-
cially in the treatment of CS or PCC patients, considered at high risk
of morbidity. To enhance the surgical performance, the operative
team should be composed by individuals usually performing jointly
a LA. In order to reduce patient risks, major intraoperative com-
plications may be laparoscopically managed only if great care is
adopted and a prompt conversion is considered in case of technical
difﬁculties.
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